Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials

BACKGROUND: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. RESULTS: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 − 0.63; p < 0.00001) and 0.87 (95% CI, 0....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Marchetti, Claudia, De Felice, Francesca, Palaia, Innocenza, Musella, Angela, Di Donato, Violante, Gasparri, Maria Luisa, Musio, Daniela, Muzii, Ludovico, Tombolini, Vincenzo, Panici, Pierluigi Benedetti
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Clinical Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914353/
https://ncbi.nlm.nih.gov/pubmed/26657509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6507
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы